Startups
Brandon Capital Partners is Australasia’s leading life science venture capital investor. As manager of the Medical Research Commercialisation Fund (MRCF), we work with scientists, clinicians and entrepreneurs from company formation and seed investment through to expansion capital, supporting life science companies from proof-of-concept through to commercialisation.
The MRCF is a unique collaboration between major Australian pension funds, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals. The MRCF supports the development and commercialisation of early-stage biomedical discoveries associated with member organisations, providing both capital and expertise to guide the successful development of new therapies. Brandon Capital currently has more than A$800 million under management and offices in Melbourne, Sydney, San Francisco and London.
For more information about Brandon Capital Partners and the MRCF, visit www.brandoncapital.com.au and www.mrcf.com.au
The MRCF is a unique collaboration between major Australian pension funds, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals. The MRCF supports the development and commercialisation of early-stage biomedical discoveries associated with member organisations, providing both capital and expertise to guide the successful development of new therapies. Brandon Capital currently has more than A$800 million under management and offices in Melbourne, Sydney, San Francisco and London.
For more information about Brandon Capital Partners and the MRCF, visit www.brandoncapital.com.au and www.mrcf.com.au
Overview
Location
Australia, New South Wales, Sydney
Employees
11-50
Founded date
2007
Mentions in press and media 21
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 7, 2026 | AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board | London, UK, 7 January 2026 – Astronautx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, today announces the appointment of Ad... |
| Oct 22, 2025 | ENA Respiratory Raises US$22.4M in Series B Financing | ENA Respiratory, a Melbourne, Australia-based clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, raised US$22.4m (AUD$34m) in Series B financ... |
| Sep 8, 2025 | NRG Therapeutics Raises £50M Series B Financing | NRG Therapeutics, a Stevenage, UK-based neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, raised £50M in Series B funding. The round was led by Health Investors’ Dementia Discovery Fund, alongside other ... |
| Sep 8, 2025 | NRG Therapeutics secures £50M Series B to advance mitochondrial drugs for ALS and Parkinson’s | Stevenage-based biotech startup NRG Therapeutics has closed a £50 million Series B funding round as it moves towards clinical trials for its pipeline of treatments targeting mitochondrial dysfunction in neurodegenerative diseases. The round... |
| Aug 28, 2025 | Vaxxas: A$90 Million Secured For Commercializing Needle-Free Vaccination Delivery Technology | Vaxxas, a biotechnology company developing the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, has secured approximately $90 million in its latest financing round. This funding, one of the largest in Australia for a... |
| Jul 28, 2025 | Brandon Capital: Fund Six Closed At Over A$439 Million | Brandon Capital, Australasia’s leading life sciences venture capital firm, has announced the final close of its sixth fund, the Brandon BioCatalyst Fund Six (BB6), totaling A$439 million. New investors in BB6 include the Western Australia G... |
| Jul 28, 2024 | CatalYm's $150 Million Bet on Cancer Resistance: A New Dawn in Immunotherapy | In the relentless battle against cancer, CatalYm has emerged as a beacon of hope. The Munich-based company recently secured $150 million in Series D funding, a significant leap forward in its mission to combat cancer therapy resistance. Thi... |
| Jul 27, 2024 | CatalYm: Cancer Therapy Resistance Mechanism Company Raises $150 Million In Series D | CatalYm announced the completion of a $150 million Series D financing. The oversubscribed funding round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde... |
| Jun 9, 2022 | Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board | Promising 'dark matter' cancer therapy has clinical trials in sight DUNEDIN, New Zealand, June 9, 2022 /PRNewswire/ -- Amaroq Therapeutics, a biotechnology company focussed on developing a new class of therapeutics that target lncRNA in can... |
Show more
Reviews 0
FAQ about Brandon Capital Partners
When was Brandon Capital Partners founded?
Brandon Capital Partners was founded in 2007.
What has the press written about Brandon Capital Partners?
Parsers VC has collected 21 articles mentioning Brandon Capital Partners, among them “AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board” (Jan 7, 2026) and “ENA Respiratory Raises US$22.4M in Series B Financing” (Oct 22, 2025).
Is Brandon Capital Partners still active?
Yes, Brandon Capital Partners is active; its latest activity on Parsers VC dates from Jul 15, 2026.